Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection
Clinical Transplantation · 2024
DOI: 10.1111/ctr.70046 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Lukas K van Vugt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Transplant Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Alemtuzumab, Graft Rejection, Kidney Transplantation, Antilymphocyte Serum. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Alemtuzumab can be an alternative to rabbit anti‐thymocyte globulin (rATG) to treat severe or glucocorticoid‐resistant acute T cell‐mediated kidney transplant rejection (TCMR). Yet, there are few reports in which these two treatments are evaluated let alone, compared. This study describes the real‐world clinical experience of both therapies and compares their efficacy and toxicity.
Methods
Kidney transplant recipients of two Dutch transplant centers who received lymphocyte‐depleting antibody therapy for severe or glucocorticoid‐resistant TCMR were retrospectively evaluated. In the first, alemtuzumab was the standard treatment for this indication, in the second, it was rATG. Patient survival, graft survival and function, and the occurrence of infections and malignancies were reported and compared.
Results
One hundred and forty‐three patients treated with alemtuzumab and 57 patients with rATG were evaluated. Patient survival was not significantly different during follow‐up ( p = 0.55), and 5‐year survival rates were 71.0% (95% confidence interval [CI]: 63.0–79.9) after alemtuzumab and 70.7% (95% CI: 58.3–85.7) after rATG. Graft survival was not significantly different during follow‐up either ( p = 0.24), and 5‐year graft loss rates were 32.3% (95% CI: 24.2–40.5) after alemtuzumab and 29.2% (95% CI: 16.0–42.4) after rATG. The occurrence of infections and malignancies did not differ between groups.
Conclusion
Mostly, severe TCMRs have good long‐term graft survival and function after either alemtuzumab or rATG therapy. No significant differences between the two therapies were found in this real‐world clinical experience. Alemtuzumab is an effective alternative to rATG for the treatment of severe TCMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erasmus MC Transplant Institute, Rotterdam, The Netherlands.
- Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Internal Medicine, Albert Schweitzer Hospital Dordrecht, Dordrecht, The Netherlands.
- Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.
ORCID-Profile: Lukas K van Vugt, Erzsi Tegzess, Marieke van der Zwan, Marian C Clahsen-van Groningen, Brenda C M de Winter, Priya Vart, Marlies E J Reinders, Jan Stephan F Sanders, Stefan P Berger, Dennis A Hesselink
Zitieren
APA
van Vugt, L. K., Tegzess, E., van der Zwan, M., Clahsen-van Groningen, M. C., de Winter, B. C. M., Vart, P., Reinders, M. E. J., Sanders, J. S. F., Berger, S. P., & Hesselink, D. A. (2024). Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection. Clinical Transplantation. https://doi.org/10.1111/ctr.70046
Vancouver
van Vugt LK, Tegzess E, van der Zwan M, Clahsen-van Groningen MC, de Winter BCM, Vart P, et al. Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection. Clinical Transplantation. 2024. doi:10.1111/ctr.70046
BibTeX
@article{vanVugt2024,
author = {van Vugt, Lukas K and Tegzess, Erzsi and van der Zwan, Marieke and Clahsen-van Groningen, Marian C and de Winter, Brenda C M and Vart, Priya and Reinders, Marlies E J and Sanders, Jan Stephan F and Berger, Stefan P and Hesselink, Dennis A},
title = {Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.70046}
}
EUVIMED